Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 149 participants.

Also called NCT01736397

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 149 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01736397
Other papers using this trial's data
  • A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5 American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015-05 DOI, PubMed 25468387

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01736397. Randomized; double masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2013-11 (actual). Results posted on 2017-10-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
Condition
Iron Deficiency
Condition
Iron Deficiency Anemia
Intervention (Drug)
Ferric Citrate
Intervention (Drug)
Placebo
Lead sponsor
Keryx Biopharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01736397
Content hash
7bb1ed8b1f845260d79caf4464acb00f7ec50d3602246cb69e42dc5939ff5a20